Biofrontera inc.BFRI.US Overview

US StockHealthcare

(No presentation for BFRI)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

BFRI Overall Performance

BFRI AI Analysis & Strategy

BFRI Recent Performance

-1.85%

Biofrontera inc.

0.81%

Avg of Sector

-1.14%

S&P500

BFRI PowerScanner

BFRI Key Information

BFRI Valuation Metrics

BFRI Earnings Table

BFRI Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.